Key Points
- Director Ray Kurzweil sold 4,910 shares at an average price of $489.02 for roughly $2.40M, cutting his stake by 27.93% to 12,670 shares (~$6.20M), and other insiders (including the CEO) also executed sizable sales the same week.
- Quarterly results showed EPS of $7.70 beating the $6.78 consensus while revenue of $790.2M missed estimates of $814.8M; the company reported a 41.9% net margin and 7.4% year‑over‑year revenue growth.
- Analyst sentiment was constructive—UBS raised its price target to $705 and multiple firms upped targets—leaving a consensus "Moderate Buy" and $539 average target, even as the stock traded near $479 (down ~1.2%) with a P/E of 17.17.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) Director Tommy Thompson sold 2,000 shares of the business's stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $489.42, for a total transaction of $978,840.00. Following the completion of the sale, the director owned 8,480 shares of the company's stock, valued at approximately $4,150,281.60. This represents a 19.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.
United Therapeutics Stock Down 0.4%
Shares of UTHR stock traded down $1.71 during mid-day trading on Friday, hitting $483.35. 60,637 shares of the stock were exchanged, compared to its average volume of 373,193. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $537.19. The firm has a fifty day moving average of $483.09 and a 200 day moving average of $451.14. The company has a market cap of $21.19 billion, a PE ratio of 17.32, a price-to-earnings-growth ratio of 1.77 and a beta of 0.84.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, topping the consensus estimate of $6.78 by $0.92. The company had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. United Therapeutics's revenue was up 7.4% compared to the same quarter last year. During the same quarter last year, the firm posted $6.19 earnings per share. Equities analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.
Wall Street Analysts Forecast Growth
UTHR has been the subject of several analyst reports. Oppenheimer boosted their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a research report on Thursday, February 26th. Weiss Ratings restated a "buy (b)" rating on shares of United Therapeutics in a research report on Monday, December 29th. Jefferies Financial Group restated a "buy" rating on shares of United Therapeutics in a report on Monday. HC Wainwright boosted their target price on shares of United Therapeutics from $525.00 to $600.00 and gave the stock a "buy" rating in a report on Thursday, February 26th. Finally, TD Cowen upped their target price on United Therapeutics from $525.00 to $575.00 and gave the stock a "buy" rating in a research note on Wednesday, February 25th. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, United Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $539.00.
Get Our Latest Stock Analysis on UTHR
Key Headlines Impacting United Therapeutics
Here are the key news stories impacting United Therapeutics this week:
- Positive Sentiment: UBS raised its price target on UTHR from $655 to $705 and maintained a Buy rating, implying roughly 45% upside vs. the current quote — a notable analyst endorsement that could attract buyers. Benzinga
- Negative Sentiment: Multiple insiders sold sizable blocks this week, creating downward pressure risk: CEO Martine A. Rothblatt sold 9,500 shares (~$4.65M) on Mar 4 (SEC filing). Directors and execs including Ray Kurzweil (4,910 sh), Tommy G. Thompson (2,000 sh) and EVP Paul A. Mahon (8,300 sh) also sold at ~$$483–$490 per share (SEC filings). The activity was flagged in a TipRanks piece summarizing the insider cash-outs. These disposals are large enough to influence sentiment even though many insiders retain significant holdings. TipRanks Rothblatt SEC Mahon SEC Kurzweil SEC Thompson SEC Causey SEC
Hedge Funds Weigh In On United Therapeutics
Large investors have recently bought and sold shares of the business. Torren Management LLC purchased a new position in shares of United Therapeutics during the fourth quarter worth $26,000. Activest Wealth Management increased its position in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company's stock valued at $29,000 after purchasing an additional 56 shares during the last quarter. WealthCollab LLC lifted its position in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 38 shares during the last quarter. Rakuten Securities Inc. increased its position in United Therapeutics by 76.7% in the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 46 shares during the period. Finally, Entrust Financial LLC purchased a new stake in shares of United Therapeutics during the 4th quarter worth $31,000. Institutional investors own 94.08% of the company's stock.
United Therapeutics Company Profile
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
